Vestibular schwannoma (VS) is a common benign intracranial tumor that often leads to progressive hearing loss (HL). Long non-coding RNA (lncRNA) plays an important regulatory role in HL. This study aims to explore the clinical significance and potential regulatory mechanisms of lncRNA PAXBP1-AS1.
No actionable change for clinical practice; this is early-stage molecular research that may eventually inform therapeutic targets but has no immediate diagnostic or treatment implications for audiologists.
Uncovering the PAXBP1-AS1/miR-124-3p axis as a potential molecular driver of hearing loss in vestibular schwannoma opens a new avenue for targeted therapies that could one day reduce surgery-associated hearing morbidity.
- 01Long non-coding RNA PAXBP1-AS1 is implicated in hearing loss associated with vestibular schwannoma.
- 02PAXBP1-AS1 appears to exert its effect by targeting and suppressing miR-124-3p, a microRNA with potential protective roles.
- 03The study adds molecular detail to the poorly understood mechanisms of schwannoma-related hearing loss.
- 04Findings are at a basic science/translational stage with no immediate clinical application.
- 05Future studies could explore PAXBP1-AS1 or miR-124-3p as biomarkers or therapeutic targets in vestibular schwannoma management.
Long non-coding RNA PAXBP1-AS1 is associated with hearing loss in vestibular schwannoma.
studypartially supportedPAXBP1-AS1 contributes to hearing loss by targeting miR-124-3p.
studypartially supported- PMID
- 42345428
- DOI
- 10.65717/iao.2026.252314.
- Journal
- International Archives of Otorhinolaryngology
- Publication type
- research_article
- Evidence level
- 4
- Population
- Patients with vestibular schwannoma and associated hearing loss
- Intervention
- Investigation of PAXBP1-AS1 long non-coding RNA and miR-124-3p interaction
Primary outcomes
Association of PAXBP1-AS1 with hearing loss in vestibular schwannoma; Mechanistic interaction between PAXBP1-AS1 and miR-124-3p